BOSS delves into the career paths of the senior executives at Australia’s 20 biggest companies to discover where they started ...

There’s long been a global shortage of the BCG vaccine for bladder cancer. But since ImmunityBio won FDA approval for Anktiva, an immunotherapy meant to be used along with the BCG vaccine, production ...

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 ...

About 72% of BCG’s largest clients were involved in at least one social or planetary impact case, said the firm’s Annual Sustainability Report ...

A novel delivery system of gemcitabine called TAR-200 led to promising responses in certain patients with non-muscle-invasive ...

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk ...

ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the Bacillus Calmette-Guérin (BCG) vaccine to treat certain patients with bladder cancer. Problem is, ...

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to ...

US chip capacity is expected to increase by 203% over the next decade, according to a report by the Semiconductor Industry ...

More companies are purchasing certificates to offset their Scope 3 emissions, a tactic that critics see as a potential new ...

Boston Consulting Group (BCG) issues a clarion call: the potential of Generative AI transcends the realms of ChatGPT. However ...

Boston Consulting Group (BCG), in collaboration with The Network and The Stepstone Group, has released a pivotal report, ...